An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection
Phase of Trial: Phase III
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics; Registrational
- Sponsors AbbVie
- 28 Aug 2017 Planned End Date changed from 31 May 2022 to 27 Apr 2022.
- 28 Jun 2017 Planned End Date changed from 26 Apr 2022 to 31 May 2022.
- 31 May 2017 Planned number of patients changed from 100 to 110.